CAJ | 학술논문

目的：定量检测鼻咽癌患者外周血中端粒酶逆转录酶催化亚单位（hTERT）mRNA的表达，并探讨其在鼻咽癌中的诊断及治疗意义。方法采用实时荧光定量PCR技术（QPCR）检测33例鼻咽癌患者治疗（放疗或化疗）前后血浆中hTERT mRNA的表达，并分析其与临床病理因素的关联，以24例健康志愿者作为对照。结果结果显示，健康志愿者血浆中hTERT mRNA相对表达量为0.95±0.37，鼻咽癌患者血浆中hTERT mRNA含量达到10.75±4.29（P<0.05）。鼻咽癌患者血浆中hTERT mRNA的表达与年龄、性别无统计学差异（P>0.05），而与临床分期、T分期及N分期有显著性差异（P<0.05）。早期患者（Ⅰ、Ⅱ期），放疗后其表达量3.43±1.42较治疗前5.60±2.33明显下降；晚期患者（Ⅲ、Ⅳ期）诱导化疗及放疗后其表达量较治疗前12.68±3.08分别降为10.68±2.48、3.13±1.69（P<0.05）。结论鼻咽癌患者血浆中hTERT mRNA的表达明显升高，放化疗能够有效抑制该基因的表达，而且该基因的含量与肿瘤的临床分期、大小及淋巴结浸润范围等临床病理因素密切相关，从而提示检测鼻咽癌患者外周血中hTERT mRNA的含量，有可能为鼻咽癌患者早期诊断及疗效判断提供重要信息。
목적：정량검측비인암환자외주혈중단립매역전록매최화아단위（hTERT）mRNA적표체，병탐토기재비인암중적진단급치료의의。방법채용실시형광정량PCR기술（QPCR）검측33례비인암환자치료（방료혹화료）전후혈장중hTERT mRNA적표체，병분석기여림상병리인소적관련，이24례건강지원자작위대조。결과결과현시，건강지원자혈장중hTERT mRNA상대표체량위0.95±0.37，비인암환자혈장중hTERT mRNA함량체도10.75±4.29（P<0.05）。비인암환자혈장중hTERT mRNA적표체여년령、성별무통계학차이（P>0.05），이여림상분기、T분기급N분기유현저성차이（P<0.05）。조기환자（Ⅰ、Ⅱ기），방료후기표체량3.43±1.42교치료전5.60±2.33명현하강；만기환자（Ⅲ、Ⅳ기）유도화료급방료후기표체량교치료전12.68±3.08분별강위10.68±2.48、3.13±1.69（P<0.05）。결론비인암환자혈장중hTERT mRNA적표체명현승고，방화료능구유효억제해기인적표체，이차해기인적함량여종류적림상분기、대소급림파결침윤범위등림상병리인소밀절상관，종이제시검측비인암환자외주혈중hTERT mRNA적함량，유가능위비인암환자조기진단급료효판단제공중요신식。
Objective To quantitatively measure plasma level of human telomerase reverse transcriptase (hTERT) mRNA in patients with nasopharyngeal carcinoma (NPC) and explore its implications for NPC diagnosis and treatment. Methods With 24 healthy volunteers serving as controls, the plasma level of hTERT mRNA was detected in 33 NPC patients by real-time PCR before and after treatments with chemotherapy or radiotherapy, and its association with the clinicopathological parameters of the patients were analyzed. Results The NPC patients showed a significantly higher mean plasma level of hTERT mRNA than the healthy volunteers (10.75±4.29 vs 0.95±0.37, P<0.05). The plasma hTERT mRNA level in the NPC patients was significantly correlated with clinical staging, tumor size, and degree of nodal metastasis (P<0.05) but with gender or age (P>0.05). In patients with stage I and II NPC, the plasma hTERT mRNA level decreased significantly after radiotherapy (5.60±2.33 vs 3.43±1.42);in patients in advanced stages (III and IV), plasma hTERT mRNA level decreased significantly from 12.68±3.08 to 10.68±2.48 (P<0.05) after chemotherapy and to 3.13 ± 1.69 (P<0.05) after radiotherapy. Conclusion Radiotherapy and chemotherapy can effectively suppress elevated plasma hTERT mRNA levels in NPC patients. Plasma hTERT mRNA level is closely related to the clinicopathological factors and provides important information for early diagnosis and therapeutic effect evaluation of NPC.